Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Kidney Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 20 - 79 |
| Updated: | 4/5/2019 |
| Start Date: | November 15, 2001 |
Case-Control Study of Renal Cell Cancer Among Caucasians and African Americans in the United States
Incidence rates of renal cell cancer have increased rapidly in the U.S. and other countries.
In particular, rates among African Americans have risen more sharply than any other cancer
site. We propose to conduct a population-based case-control study of renal cell cancer in
areas of the U.S. with a high proportion of African American residents. We will include two
study centers and one data coordinating center and will recruit study participants over a
period of four years. We plan to conduct in-person interviews with 2,100 cases (1,400 whites
and 700 blacks) and 2,800 controls (1,400 each of whites and blacks) to elicit information on
demographic background and history of exposures. A 40 ml blood sample will be collected from
living cases and controls to measure certain environmental exposures and for genetic
analyses. Two buccal cell samples will be collected from living cases and controls for
genetic analyses. Tumor tissue blocks will be collected from as many cases as possible for
assays of tumor mutations. Diagnostic slides will be collected for standardized
reclassification of tumors into clear cell, papillary, and other histologic subtypes. Medical
records for all cases will be reviewed for health insurance coverage, concomitant conditions,
presenting symptoms, tumor stage, size and grade, and methods leading to diagnosis of renal
cell cancer.
In particular, rates among African Americans have risen more sharply than any other cancer
site. We propose to conduct a population-based case-control study of renal cell cancer in
areas of the U.S. with a high proportion of African American residents. We will include two
study centers and one data coordinating center and will recruit study participants over a
period of four years. We plan to conduct in-person interviews with 2,100 cases (1,400 whites
and 700 blacks) and 2,800 controls (1,400 each of whites and blacks) to elicit information on
demographic background and history of exposures. A 40 ml blood sample will be collected from
living cases and controls to measure certain environmental exposures and for genetic
analyses. Two buccal cell samples will be collected from living cases and controls for
genetic analyses. Tumor tissue blocks will be collected from as many cases as possible for
assays of tumor mutations. Diagnostic slides will be collected for standardized
reclassification of tumors into clear cell, papillary, and other histologic subtypes. Medical
records for all cases will be reviewed for health insurance coverage, concomitant conditions,
presenting symptoms, tumor stage, size and grade, and methods leading to diagnosis of renal
cell cancer.
Incidence rates of renal cell cancer have increased rapidly in the U.S. and other countries.
In particular, rates among African Americans have risen more sharply than any other cancer
site. We propose to conduct a population-based case-control study of renal cell cancer two
areas of the U.S. with a high proportion of African American residents: Detroit, Michigan
(Wayne State University), and Chicago, Illinois (University of Illinois at Chicago). Westat,
Inc. is the coordinating center. Participants are being recruited over a period of four
years. A total of 2,100 cases (1,400 Caucasian Americans and 700 African Americans) and 2,800
controls (1,400 each of Caucasian and African Americans) will be recruited. In-person
interviews are conducted with cases and controls to elicit information on demographic
background and history of exposures. A 40 ml blood sample and a buccal cell sample are
collected from cases and controls for genetic analyses. Tumor tissue blocks will be collected
from as many cases as possible for assays of tumor mutations. Diagnostic slides will be
collected for standardized reclassification of tumors into clear cell, papillary, and other
histologic subtypes. Medical records for all cases will be reviewed for presenting symptoms,
tumor stage, size and grade, and methods leading to diagnosis of renal cell cancer. Telephone
interviews are conducted with the nest-of-kin of eligible cases who died before we could
interview them. Permission is being sought from the next-of-kin to assess the case's medical
records and obtain tumor tissue samples.
In particular, rates among African Americans have risen more sharply than any other cancer
site. We propose to conduct a population-based case-control study of renal cell cancer two
areas of the U.S. with a high proportion of African American residents: Detroit, Michigan
(Wayne State University), and Chicago, Illinois (University of Illinois at Chicago). Westat,
Inc. is the coordinating center. Participants are being recruited over a period of four
years. A total of 2,100 cases (1,400 Caucasian Americans and 700 African Americans) and 2,800
controls (1,400 each of Caucasian and African Americans) will be recruited. In-person
interviews are conducted with cases and controls to elicit information on demographic
background and history of exposures. A 40 ml blood sample and a buccal cell sample are
collected from cases and controls for genetic analyses. Tumor tissue blocks will be collected
from as many cases as possible for assays of tumor mutations. Diagnostic slides will be
collected for standardized reclassification of tumors into clear cell, papillary, and other
histologic subtypes. Medical records for all cases will be reviewed for presenting symptoms,
tumor stage, size and grade, and methods leading to diagnosis of renal cell cancer. Telephone
interviews are conducted with the nest-of-kin of eligible cases who died before we could
interview them. Permission is being sought from the next-of-kin to assess the case's medical
records and obtain tumor tissue samples.
- INCLUSION CRITERIA - CASES:
Residents of the study areas who are diagnosed with histologically confirmed renal cell
carcinoma at ages 20 to 79 years over a four year study will be potentially eligible for
the study.
In addition, only eligible patients who are mentally/physically able to provide informed
consent and undergo interviews will be approached for participation.
INCLUSION CRITERIA - CONTROLS:
Population-based controls will be frequency-matched to the cases by study center, race, age
and sex, at the ratio of one control per case for non-African Americans and two controls
per case for African Americans.
Controls aged 65 years and older will be identified from Health Care Financing
Administration (HCFA) files.
Controls under age 65 years will be identified from residents of the study areas by random
telephone digit dialing (RDD).
We found this trial at
2
sites
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
Click here to add this to my saved trials
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials